These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction.
|
|
|
|
(5)
|
Total fee paid:
|
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
(2)
|
Form, Schedule, or Registration Statement No.:
|
|
|
|
(3)
|
Filing Party:
|
|
|
|
(4)
|
Date Filed.
|
|
|
|
1.
|
To elect the five directors nominated and recommended by the Board of Directors, each to serve until the 2020 Annual Meeting of Stockholders or until such time as their respective successors are elected and qualified;
|
|
2.
|
To hold an advisory vote on executive compensation;
|
|
3.
|
To ratify the appointment of PricewaterhouseCoopers LLP to serve as our independent registered public accounting firm for the year ending December 31, 2019; and
|
|
4.
|
To transact such other business, if any, properly brought before the meeting.
|
|
|
|
|
|
Q.
|
How will we solicit proxies for the Annual Meeting?
|
|
A.
|
We are soliciting proxies by furnishing this Proxy Statement and proxy card to our stockholders. In addition, some of our directors and officers and certain employees of EMG may make additional solicitations by telephone or in person without additional compensation for such activities. We will pay the solicitation costs and will reimburse banks, brokerage houses and other custodians, nominees and fiduciaries for their reasonable expenses in forwarding proxy materials to beneficial owners.
|
|
Q.
|
Who is entitled to vote?
|
|
A.
|
All stockholders of record as of the close of business on March 22, 2019, which is the record date, are entitled to notice of and to vote at the Annual Meeting.
|
|
Q.
|
What is the quorum for the Annual Meeting?
|
|
A.
|
The presence at the Annual Meeting, in person or by proxy, of a majority of the votes entitled to be cast by the holders of all outstanding shares of common stock, par value $0.001 per share, of the Company, or "Common Shares," will constitute a quorum for the transaction of business. No business may be conducted at the meeting if a quorum is not present. As of the record date, 29,745,776 Common Shares were issued and outstanding. The chairman of the meeting may adjourn the Annual Meeting to another time or place whether or not a quorum is present at the Annual Meeting. If a Common Share is deemed present at the Annual Meeting for any matter, it will be deemed present for all other matters. Pursuant to Delaware law, abstentions are treated as present for quorum purposes.
|
|
Q.
|
How many votes do I have?
|
|
A.
|
You are entitled to one vote for each whole Common Share you held as of the record date. Our stockholders do not have the right to cumulate their votes for directors.
|
|
Q.
|
How do I vote my shares prior to the Annual Meeting?
|
|
A.
|
If you are a stockholder of record, meaning that your Common Shares are registered in your name, you have three voting options. You may vote:
|
|
Q.
|
Can I vote my shares during the Annual Meeting?
|
|
A.
|
You may vote your shares during the Annual Meeting by visiting www.virtualshareholdermeeting.com/EFC2019 and following the instructions. You will need the 16-digit control number included in your proxy card, voting instruction form or Notice of Internet Availability of Proxy Materials. You will be able to vote during the Annual Meeting until such time as the Chairman declares the polls closed.
|
|
Q.
|
How do I vote my Common Shares that are held by my broker?
|
|
A.
|
If you hold your Common Shares in "street name" through an account with a broker or bank, you may instruct your broker or bank to vote your Common Shares or revoke your voting instructions by following the instructions that the broker provides to you. Most brokers allow you to authorize your proxy by mail and on the Internet.
|
|
Q.
|
What am I voting on?
|
|
A.
|
You will be voting on:
|
|
Q.
|
What vote is required to approve the proposals assuming that a quorum is present at the Annual Meeting?
|
|
Proposal
|
|
Vote Requirement
|
|
Proposal 1: Election of Directors
|
|
A plurality of the votes cast for the election of each director nominee. The five nominees who receive the most votes will be elected.
|
|
Proposal 2: An Advisory (Non-Binding) "Say on Pay" Vote to Approve Executive Compensation
|
|
The affirmative vote of a majority of Common Shares present in person or represented by proxy at the Annual Meeting and entitled to vote on the matter. Voting for Proposal 2 is being conducted on an advisory basis and, therefore, the voting results will not be binding on the Company, the Board of Directors or the Compensation Committee.
|
|
Proposal 3: Ratification of Appointment of Our Independent Registered Public Accounting Firm for 2019
|
|
The affirmative vote of a majority of Common Shares present in person or represented by proxy at the Annual Meeting and entitled to vote on the matter.
|
|
Proposal
|
|
Treatment of Abstentions and Broker Non-Votes
|
|
Proposal 1: Election of Directors
|
|
Abstentions and Common Shares not represented at the Annual Meeting will have no effect on the election of directors. Brokers are not entitled to vote on director elections and thus broker non-votes are not treated as votes cast and will have no effect on the election of directors.
|
|
Proposal 2: An Advisory (Non-Binding) "Say on Pay" Vote to Approve Executive Compensation
|
|
Abstentions will have the same effect as a vote against this proposal, whereas broker non-votes and Common Shares not otherwise represented at the Annual Meeting will have no effect on the outcome of this proposal.
|
|
Proposal 3: Ratification of Appointment of Our Independent Registered Public Accounting Firm for 2019
|
|
Abstentions will have the same effect as a vote against this proposal, whereas Common Shares not represented at the meeting will not be counted for purposes of determining whether such matter has been approved. Because this is considered a routine matter under NYSE rules, broker non-votes will not arise in connection with, and thus will have no effect on, this proposal.
|
|
Q.
|
Will there be any other items of business on the agenda?
|
|
A.
|
The Board of Directors does not know of any other matters that may be brought before the Annual Meeting nor does it foresee or have reason to believe that proxy holders will have to vote for substitute or alternate nominees for election to the Board of Directors. In the event that any other matter should come before the Annual Meeting or any nominee is not available for election, the persons named in the enclosed proxy will have discretionary authority to vote all proxies with respect to such matters in accordance with their discretion.
|
|
Q.
|
What happens if I submit my proxy without providing voting instructions on one or more proposals?
|
|
A.
|
Proxies properly submitted will be voted at the Annual Meeting in accordance with your directions. If the properly submitted proxy does not provide voting instructions on a proposal, the proxy will be voted, except in the case of a broker non-vote, to elect (FOR) each of the director nominees listed in "Proposal 1—Election of Directors," in favor of (FOR) "Proposal 2—An Advisory (Non-Binding) 'Say on Pay' Vote to Approve Executive Compensation," and in favor of (FOR) "Proposal 3—Ratification of the Appointment of Independent Registered Public Accounting Firm for 2019."
|
|
Q.
|
Will anyone contact me regarding this vote?
|
|
A.
|
No arrangements or contracts have been made with any solicitors as of the date of this Proxy Statement, although we reserve the right to engage solicitors if we deem them necessary. Solicitations may be made by mail, telephone, facsimile, e-mail, or personal interviews.
|
|
Q.
|
Who will pay for this proxy solicitation?
|
|
A.
|
We will pay the entire expense of preparing, printing, and mailing the proxy materials and any additional materials furnished to stockholders. Proxies may be solicited by our directors and officers and certain employees of EMG personally or by telephone without additional compensation for such activities. We also will request persons, firms, and corporations holding Common Shares in their names or in the names of their nominees, which are beneficially owned by others, to send appropriate solicitation materials to such beneficial owners. We will reimburse such holders for their reasonable expenses.
|
|
Q.
|
May stockholders ask questions at the Annual Meeting?
|
|
A.
|
Yes. You may vote and submit questions while attending the meeting online. You will need the sixteen-digit control number included on your Notice of Internet Availability of Proxy Materials, your proxy card or on the instructions that accompanied your proxy materials in order to be able to enter the meeting.
|
|
Q.
|
What does it mean if I receive more than one proxy card?
|
|
A.
|
It probably means your Common Shares are registered differently and are in more than one account. Sign and return all proxy cards, or vote by the methods provided by your broker to ensure that all your Common Shares are voted.
|
|
Q.
|
Can I change my vote after I have voted?
|
|
A.
|
Yes. A stockholder may revoke a proxy at any time prior to its exercise by filing with our Secretary a duly executed revocation of proxy, by properly submitting by mail a proxy to our Secretary bearing a later date or by attending the meeting online and voting. Attendance at the meeting will not by itself constitute revocation of a proxy.
|
|
Q.
|
Can I find additional information on the Company's website?
|
|
A.
|
Yes. Our Internet website is located at www.ellingtonfinancial.com. Although the information contained on our website is not part of this Proxy Statement, you can view additional information on the website, such as our Corporate Governance Guidelines, our Code of Business Conduct and Ethics, charters of the committees of our Board and reports that we file with the Securities and Exchange Commission, or "SEC."
|
|
Name and Position
With Our Company
|
|
Age
|
|
Background Summary
|
|
Thomas F. Robards
Chairman of the Board
|
|
72
|
|
Mr. Robards has served as a member of our Board and as Chairman of our Audit Committee since August 2007 and as our Chairman since October 2009. Mr. Robards has been a principal in Robards & Co, LLC, a private investment and advisory company, since July 2005. He currently serves as Chairman of the Board of Trustees and is a member of the audit committee of the HSBC Funds, a mutual fund complex. He currently serves as Chairman of the Board of Trustees of Ellington Residential Mortgage REIT, a NYSE-listed company that is externally managed by an affiliate of EMG, a position he has held since May 2013. He previously was a Director and Audit Committee Chair of Overseas Shipholding Group, Inc. from April 2005 until August 2014, and until December of 2006 was a Director and on the Audit Committee of Financial Federal Corporation, both NYSE-listed companies. From 2003 to 2004, he was the Senior Vice President and Chief Financial Officer of the American Museum of Natural History in New York, New York. He was the Chief Financial Officer for Datek Online Holding Corporation from 2000 until its acquisition by Ameritrade in 2002. Prior to that, Mr. Robards was employed at Republic New York Corporation for 24 years, including as Chief Financial Officer and Executive Vice President, and from 1997 to 1999 served on its Board of Directors. During his tenure his responsibilities at Republic included leading its Asset/Liability and Finance Committees as well as managing Republic National Bank treasury and investment portfolio activities. Mr. Robards earned his B.A. from Brown University and an M.B.A. from Harvard Business School.
Our Board believes that Mr. Robards' expertise in finance and accounting, including knowledge of financial institutions, public accounting, internal controls, audit committee performance and governance matters, and experience amassed from past and current service on the audit committees of NYSE-listed companies, give him the qualifications and skills to serve as a director of our Company. |
|
|
|
|
|
|
|
Name and Position
With Our Company
|
|
Age
|
|
Background Summary
|
|
Laurence Penn
Chief Executive Officer, President & Director
|
|
57
|
|
Mr. Penn has been our Chief Executive Officer and President and has served as a member of our Board of Directors since our inception in 2007. Mr. Penn is also a Vice Chairman of EMG, where he helps oversee many functions of the firm. Mr. Penn is also the Executive Vice President of our Manager and serves on EMG's Investment and Risk Management Committee. Mr. Penn also serves as Chief Executive Officer, President and a member of the Board of Trustees of Ellington Residential Mortgage REIT. Mr. Penn has also served as a Trustee of Ellington Income Opportunities Fund, a closed-end management investment company, since October 2018. In EMG's earlier years, Mr. Penn was the senior portfolio manager primarily responsible for investments in Agency RMBS. Prior to joining EMG in 1995 shortly after its inception, Mr. Penn was at Lehman Brothers where he was a Managing Director and co-head of CMO origination and trading. Mr. Penn began his career at Lehman Brothers in 1984, after receiving a Master of Advanced Study in Mathematics from Cambridge University, where he studied as both a National Science Foundation and Winston Churchill Scholar. Mr. Penn graduated summa cum laude, Phi Beta Kappa with a B.A. in Mathematics from Harvard University in 1983. He was one of five winners nationwide in the 1980 Putnam collegiate mathematics problem solving competition, and represented the United States in the 21st International Mathematics Olympiad held in London, England.
Our Board believes that Mr. Penn's operational experience as President and Chief Executive Officer of our Company, risk management and trading expertise and, in particular, his extensive experience in the mortgage securities business, give him the qualifications and skills to serve as a director of our Company. |
|
|
|
|
|
|
|
Ronald I. Simon, Ph.D.
Director
|
|
80
|
|
Dr. Simon has served as a member of our Board since August 2007. Dr. Simon has served as a member of the Board of Trustees and as the Chairman of the Nominating and Corporate Governance Committee of Ellington Residential Mortgage REIT since May 2013. Dr. Simon is a private investor and financial consultant to businesses. From March 2003 through February 2006, when it was acquired by Wachovia Corp., Dr. Simon was a Director of WFS Financial, Inc., a publicly-traded financial services company specializing in automobile finance. He was a director of Collateral Therapeutics from 1998 until its acquisition by Schering A.G. in 2002. From January 2006 to January 2009, he was a director of Cardium Therapeutics, a company formed to acquire and carry on the research and development of gene therapy to treat heart disease, which was originally developed by Collateral Therapeutics and then continued by Schering. From 1995 through 2002, Dr. Simon was a director of SoftNet Systems, Inc., and from 2002 through August 2016 he was a director of its successor company, American Independence Corp., a holding company engaged principally in the health insurance and reinsurance business. Since August 2016, Dr. Simon has served as a director, and since November 2017, as a member of the Audit Committee, of Independence Holdings Company, a holding company principally engaged in the life and health insurance business, and the successor company to American Independence Corp. He was a director of BDI Investment Corporation, a closely held regulated investment company, from February 2003 until its liquidation in early 2005, and served as Chief Financial Officer for Wingcast, LLC, a developer of automotive telematics from 2001 to 2002. During 2001, Dr. Simon served as Acting Chairman, Chief Executive Officer, and Chief Financial Officer for SoftNet Systems, Inc. He also served as Executive Vice President and Chief Financial Officer of Western Water Company from 1997 to 2000, and a director of Western Water Company from 1999 through 2001. Dr. Simon earned a B.A. from Harvard University, an M.A. from Columbia University, and a Ph.D. from Columbia University Graduate School of Business.
Our Board believes that Dr. Simon's expertise in finance and his extensive service in senior officer positions and directorships of public companies in a variety of industries give him the qualifications and skills to serve as a director of our Company. |
|
Name and Position
With Our Company
|
|
Age
|
|
Background Summary
|
|
Edward Resendez
Director
|
|
62
|
|
Mr. Resendez has served as a member of our Board since August 2007. From November 2013 through February 2018, Mr. Resendez served as Vice Chairman, President and Chief Operating Officer of Cherrywood Commercial Lending, LLC, or "Cherrywood." Cherrywood is a small-balance commercial mortgage origination, securitization, and finance company. Beginning in March 2018, Mr. Resendez serves in the same position with Cherrywood Mortgage, LLC, the successor company to Cherrywood. From 2007 to September 2009, Mr. Resendez was Senior Vice President-Chief Lending Officer of Kinecta Federal Credit Union and President of Kinecta Alternative Financial Solutions, Inc. From 2002 to 2007, Mr. Resendez was Chief Executive Officer, Board Member and Co-Founder of ResMAE Financial Corporation and its wholly-owned subsidiary ResMAE Mortgage Corporation, or "ResMAE." From 1995 through 2000, Mr. Resendez was the President of Long Beach Mortgage Company. During that timeframe he was also appointed as President and a Management Member of the board of directors for both Long Beach Financial Corporation, when that company went public in 1997 (formerly NASDAQ symbol: LBFC), and its wholly-owned operating subsidiary, Long Beach Mortgage Company, a subprime mortgage company, or, collectively with Long Beach Financial Corporation, "Long Beach." Long Beach was an originator, purchaser, seller and servicer of subprime mortgages. From 1987 to 1995, Mr. Resendez held various management positions at Long Beach, including Executive Vice President—Loan Administration, First Vice President—Risk Management, Vice President—REO Loan Servicing, and Vice President—Retail Origination. Prior to joining Long Beach in 1987, Mr. Resendez held several managerial positions with Transamerica Financial Services from 1977 to 1987. Mr. Resendez earned a B.B.A. from Loyola Marymount University in Los Angeles in 1978, and is a licensed real estate broker in California.
Our Board believes that Mr. Resendez's extensive operational experience in and knowledge of the mortgage lending business give him the qualifications and skills to serve as a director of our Company. |
|
|
|
|
|
|
|
Lisa Mumford
Director
|
|
55
|
|
Ms. Mumford served as the Company's Chief Financial Officer ("CFO") and the Chief Financial Officer of Ellington Financial Management LLC, the Company's external manager, from October 2009 through her retirement in March 2018. Ms. Mumford also served as the Chief Financial Officer of Ellington Residential Mortgage REIT ("EARN") from April 2013 until her retirement in March 2018. As CFO of the Company and EARN, Ms. Mumford managed all aspects of the accounting, internal control, and financial reporting processes. From August 2008 to October 2009, Ms. Mumford was Chief Financial Officer of ACA Financial Guaranty Corporation, or "ACA FG," where she oversaw all aspects of the finance and accounting operations. From 2003 until August 2008, Ms. Mumford served as the Chief Accounting Officer of ACA Capital Holdings, Inc., or "ACA," of which ACA FG was an operating subsidiary. Prior to joining ACA, and beginning in 1988, Ms. Mumford was with ACE Guaranty Corp., where over her tenure she held the positions of Chief Financial Officer and Controller. She began her career as a staff accountant with Coopers & Lybrand in 1984, culminating in the role of Audit Supervisor at the time of her departure in 1988. Ms. Mumford is a member of the American Institute of Certified Public Accountants and holds a B.B.A. in Accounting from Hofstra University.
Our Board believes that Ms. Mumford's operational experience as the former Chief Financial Officer of our Company and, in particular, her extensive experience in preparing and reviewing financial statements for financial services companies, give her the qualifications and skills to serve as a director of our Company.
|
|
|
2018
|
|
2017
|
||||
|
Audit Fees
|
$
|
1,617,800
|
|
|
$
|
1,710,720
|
|
|
Audit-related Fees
|
12,600
|
|
|
12,600
|
|
||
|
Tax Fees
|
500,000
|
|
|
—
|
|
||
|
All Other Fees
|
1,818
|
|
|
1,818
|
|
||
|
Total Fees
|
$
|
2,132,218
|
|
|
$
|
1,725,138
|
|
|
1.
|
A director who is, or who has been within the last three years, an employee of our Company or any of its affiliates, or whose immediate family member is, or has been within the last three years, an executive officer of our Company or any of its affiliates.
|
|
2.
|
A director who has received or who has an immediate family member, serving as an executive officer, who has received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from our Company (excluding director and committee fees, and pension/other forms of deferred compensation for prior service that is not contingent in any way on continued service).
|
|
3.
|
(A) A director who is or whose immediate family member is a current partner of a firm that is our internal or external auditor; (B) a director who is a current employee of such a firm; (C) a director who has an immediate family member who is a current employee of such a firm and who personally works on our audit; or (D) a director who was or whose immediate family member was within the last three years (but is no longer) a partner or employee of such a firm and personally worked on our audit within that time.
|
|
4.
|
A director who is or has been within the last three years, or whose immediate family member is, or has been within the last three years, employed as an executive officer of another company where any of our present executives at the same time serves or served on that company's compensation committee.
|
|
5.
|
A director who is a current employee, or whose immediate family member is a current executive officer, of a company that has made payments to, or received payments from, us for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1 million or 2% of such other company's consolidated gross revenues (as reported for the last completed fiscal year).
|
|
Director Name
|
|
Audit
Committee
|
|
Compensation
Committee
|
|
Nominating and
Corporate
Governance
Committee
|
|
Edward Resendez
|
|
Member
|
|
Chair
|
|
Member
|
|
Thomas F. Robards
|
|
Chair
|
|
Member
|
|
Member
|
|
Ronald I. Simon, Ph.D.
|
|
Member
|
|
Member
|
|
Chair
|
|
Number of Meetings in 2017
|
|
7
|
|
6
|
|
2
|
|
•
|
honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
|
|
•
|
compliance with applicable governmental laws, rules, and regulations;
|
|
•
|
prompt internal reporting of violations of the code to appropriate persons identified in the Code of Business Conduct and Ethics; and
|
|
•
|
accountability for adherence to the Code of Business Conduct and Ethics.
|
|
Name
|
|
Fees Earned
or Paid in
Cash
|
|
LTIP
Unit
Awards
(1)
|
|
All Other Compensation
(2)
|
|
Total Compensation
|
|||||||||
|
Thomas F. Robards
|
|
$
|
103,000
|
|
|
$
|
57,500
|
|
(3)
|
|
$
|
5,581
|
|
|
$
|
166,081
|
|
|
Ronald I. Simon, Ph.D.
|
|
70,500
|
|
|
57,500
|
|
(4)
|
|
5,581
|
|
|
133,581
|
|
||||
|
Edward Resendez
|
|
70,500
|
|
|
57,500
|
|
(5)
|
|
5,581
|
|
|
133,581
|
|
||||
|
Lisa Mumford
(6)
|
|
26,250
|
|
|
57,500
|
|
(7)
|
|
29,944
|
|
|
113,694
|
|
||||
|
Laurence Penn
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
||||
|
Michael W. Vranos
(8)
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
||||
|
(1)
|
All share-based awards were granted pursuant to the 2017 Plan. The aggregate grant date fair value was calculated in accordance with the Financial Accounting Standards Board's, or "FASB," Accounting Standards Codification, or "ASC," Topic 718 based on the closing sale price for our Common Shares on the NYSE on the date of grant.
|
|
(2)
|
Amounts reflect dividends paid on unvested LTIP Units in 2018.
|
|
(3)
|
Mr. Robards received 3,610 LTIP Units with a grant date fair value of $57,500. These LTIP Units were granted on September 12, 2018 and will vest, subject to certain limitations, on September 11, 2019. As of December 31, 2018, Mr. Robards had outstanding an aggregate of 22,771 LTIP Units, 19,161 of which had vested.
|
|
(4)
|
Dr. Simon received 3,610 LTIP Units with a grant date fair value of $57,500. These LTIP Units were granted on September 12, 2018 and will vest, subject to certain limitations, on September 11, 2019. As of December 31, 2018, Dr. Simon had outstanding an aggregate of 3,610 LTIP Units, none of which had vested.
|
|
(5)
|
Mr. Resendez received 3,610 LTIP Units with a grant date fair value of $57,500. These LTIP Units were granted on September 12, 2018, and will vest, subject to certain limitations, on September 11, 2019. As of December 31, 2018, Mr. Resendez had outstanding an aggregate of 21,521 LTIP Units, 17,911 of which had vested.
|
|
(6)
|
Ms. Mumford, our former Chief Financial Officer, joined our the Board on August 1, 2018, and received a pro rated portion of the annual retainer.
|
|
(7)
|
Ms. Mumford received 3,610 LTIP Units with a grant date fair value of $57,500. These LTIP Units were granted on September 12, 2018, and will vest, subject to certain limitations, on September 11, 2019. As of December 31, 2018, Ms. Mumford had outstanding an aggregate of 65,107 LTIP Units, 55,611 of which had vested.
|
|
(8)
|
Mr. Vranos resigned from the Board on August 1, 2018, and continues to serve as our Co-Chief Investment Officer.
|
|
•
|
Cross Transactions
—defined as transactions between us or one of our subsidiaries, on the one hand, and an account (other than us or one of our subsidiaries) managed by EMG or our Manager, on the other hand. It is EMG policy to engage in a cross transaction only when the transaction is in the best interests of, and is consistent with the objectives and policies of, both accounts involved in the transaction. EMG or our Manager may enter into cross transactions where it acts both on our behalf and on behalf of the other party to the transaction. Upon written notice to our Manager, we may at any time revoke our consent to our Manager's executing cross transactions. Additionally, unless approved in advance by a majority of our independent directors or pursuant to and in accordance with a policy that has been approved by a majority of our independent directors, all cross transactions must be effected at the then-prevailing market prices. Pursuant to our Manager's current policies and procedures, assets for which there are no readily observable market prices may be purchased or sold in cross transactions (1) at prices based upon third party bids received through auction, (2) at the average of the highest bid and lowest offer quoted by third party dealers, or (3) according to another pricing methodology approved by our Manager's Chief Compliance Officer.
|
|
•
|
Principal Transactions
—defined as transactions between EMG or our Manager (or any related party of EMG or our Manager, which includes employees of EMG and our Manager and their families), on the one hand, and us or one of our subsidiaries, on the other hand. Certain cross transactions may also be considered principal transactions whenever our Manager, EMG (or any related party of EMG or our Manager, which includes employees of EMG and our Manager and their families) have a substantial ownership interest in one of the transacting parties. Our Manager is only authorized to execute principal transactions with the prior approval of a majority of our independent directors and in accordance with applicable law. Such prior approval includes approval of the pricing methodology to be used, including with respect to assets for which there are no readily observable market prices.
|
|
•
|
Investment in other EMG accounts
—pursuant to our management agreement, if we invest at issuance in the equity of any collateralized debt obligation, or "CDO," that is managed, structured or originated by EMG or one of its affiliates, or if we invest in any other investment fund or other investment for which EMG or one of its affiliates receives management, origination or structuring fees, then, unless agreed otherwise by a majority of the Company's independent directors, the base management and incentive fees payable by us to our Manager will be reduced by an amount equal to the applicable portion (as described in the management agreement) of any such management fees, origination fees or structuring fees.
|
|
•
|
Split price executions
—pursuant to our management agreement, our Manager is authorized to combine purchase or sale orders on our behalf together with orders for other accounts managed by EMG, our Manager or their affiliates and allocate the securities or other assets so purchased or sold, on an average price basis or other fair and consistent basis, among such accounts.
|
|
Name and Position
With Our Company
|
|
Age
|
|
Background Summary
|
|
Laurence Penn
Chief Executive Officer, President & Director
|
|
57
|
|
See "Proposal 1: Election of Directors—Information Regarding the Nominees."
|
|
|
|
|
|
|
|
Michael W. Vranos
Co-Chief Investment Officer
|
|
57
|
|
Mr. Vranos has been our Co-Chief Investment Officer since June 2009 and served as a member of our Board of Directors from our inception in 2007 until August 2018. From our inception in 2007 until October 2009, Mr. Vranos served as our Chairman and is also the Chief Executive Officer and President of our Manager. Mr. Vranos also serves as Co-Chief Investment Officer and as a member of the Board of Trustees of Ellington Residential Mortgage REIT. Mr. Vranos is also the founder and Chief Executive Officer of EMG, which he founded in December of 1994 to capitalize on distressed conditions in the mortgage-backed securities, or "MBS," derivatives market. Until December 1994, he was the Senior Managing Director of Kidder Peabody, in charge of residential mortgage-backed securities, or "RMBS," trading. Mr. Vranos graduated magna cum laude, Phi Beta Kappa with a B.A. in Mathematics from Harvard University.
|
|
|
|
|
|
|
|
Mark Tecotzky
Co-Chief Investment Officer
|
|
57
|
|
Mr. Tecotzky has been our Co-Chief Investment Officer since March 2008, the Co-Chief Investment Officer of Ellington Residential Mortgage REIT since October 2012, and serves as the Co-Chief Investment Officer of our Manager. Mr. Tecotzky is also a Managing Director of EMG, and head portfolio manager for all MBS/ABS credit, reporting directly to Mr. Vranos. Prior to joining EMG in July 2006, Mr. Tecotzky was the senior trader in the mortgage department at Credit Suisse. He developed and launched several of its securitization vehicles, including hybrid adjustable-rate mortgages, or "ARMs," and second liens, and subsequently ran its hybrid ARM business, including conduit pricing, servicing sales, monthly securitization, trading of Agency/non-Agency hybrids of all ratings categories, and managing and hedging the residual portfolio. Prior to joining Credit Suisse, Mr. Tecotzky worked with Mr. Vranos and many of the other EMG principals at Kidder Peabody, and traded Agency and non-Agency pass-throughs and structured CMOs as a Managing Director. Mr. Tecotzky holds a B.S. from Yale University and received a National Science Foundation fellowship to study at MIT.
|
|
|
|
|
|
|
|
JR Herlihy
Chief Financial Officer
|
|
37
|
|
Mr. Herlihy joined EMG in April 2011 and has been our Chief Financial Officer since April 2018 and our Treasurer since May 2017. In addition, Mr. Herlihy has also been the Chief Operating Officer of EMG's other public company affiliate, Ellington Residential Mortgage REIT (NYSE: EARN), since April 2018 and its Treasurer since May 2017. Mr. Herlihy is also a Director at EMG, where he has served in various capacities, including serving as Co-Chief Investment Officer of our former affiliate, Ellington Housing Inc. ("EHR"), a real estate investment trust that was focused on single- and multi-family residential real estate assets, from EHR's inception in September 2012 through December 2016. Mr. Herlihy also served as EHR's Interim Chief Financial Officer from March 2015 through January 2016. Prior to April 2011, Mr. Herlihy held various positions in the real estate industry, including at the real estate private equity firm GTIS Partners LP, Capmark Financial Group (formerly GMAC Commercial Mortgage), and Jones Lang LaSalle. Mr. Herlihy earned a B.A. in Economics and History from Dartmouth College, summa cum laude and Phi Beta Kappa.
|
|
|
|
|
|
|
|
Christopher Smernoff
Chief Accounting Officer
|
|
42
|
|
Mr. Smernoff joined Ellington in January 2007 and has served as our Chief Accounting Officer since April 2018. Mr. Smernoff also served as our Controller from February 2010 until April 2018. Mr. Smernoff is responsible for managing all aspects of our finance and accounting operations. In addition, Mr. Smernoff has served as the Chief Financial Officer of Ellington Residential Mortgage REIT (NYSE: EARN) since April 2018. Prior to that Mr. Smernoff served as EARN's controller since April 2013. From January 2007 through February 2010, Mr. Smernoff was an Assistant Controller for various private entities managed by EMG. Prior to January 2007, Mr. Smernoff was employed as a manager in the assurance practice of PricewaterhouseCoopers LLP, where he was primarily focused on providing audit and accounting services to a variety of clients in the investment management industry. Mr. Smernoff is a member of the American Institute of Certified Public Accountants and holds a B.S. in Accounting and Finance from Boston College.
|
|
|
|
|
|
|
|
Daniel Margolis
General Counsel
|
|
45
|
|
Mr. Margolis has been our General Counsel since August 2013 and also served as our Secretary from July 2010 to August 2013. Mr. Margolis has also served as General Counsel of EMG since July 2010 and of Ellington Residential Mortgage REIT since April 2013. He is responsible for advising EMG on all legal, regulatory, compliance, documentation, and litigation matters. Prior to joining EMG, Mr. Margolis was a Partner at Pillsbury, Winthrop, Shaw, Pittman LLP from 2007 to 2010 and before that was a Junior Partner at Wilmer, Cutler, Pickering, Hale and Dorr LLP from 2004 to 2007. In both positions, Mr. Margolis represented corporations and individuals, including financial services organizations, in criminal and regulatory investigations and in complex civil litigation. From 2000 to 2004, he served as an Assistant United States Attorney in the United States Attorney's Office for the Southern District of New York where he prosecuted a variety of white collar crimes including securities fraud, investment fraud, tax fraud, and money laundering. In 2004, he received the John Marshall Award, the Department of Justice's highest award for excellence in legal performance. He has a J.D. from New York University Law School, where he graduated cum laude, and a B.A. from Binghamton University where he graduated magna cum laude with highest honors in Political Science and was a member of Phi Beta Kappa.
|
|
•
|
retain and motivate our partially dedicated Chief Financial Officer and our partially dedicated Chief Accounting Officer by providing fair compensation;
|
|
•
|
encourage share ownership by providing a portion of compensation through OP LTIP Units; and
|
|
•
|
align management incentives with the long-term interests of our stockholders.
|
|
Name and Principal Position
|
|
Year
|
|
Salary
(1)
|
|
Bonus
(2)
|
|
Stock
Awards
(3)
|
|
All Other Compensation
(4)
|
|
Total
|
||||||||||
|
JR Herlihy
Chief Financial Officer (5) |
|
2018
|
|
$
|
158,400
|
|
|
$
|
166,320
|
|
|
$
|
166,330
|
|
|
$
|
—
|
|
|
$
|
491,050
|
|
|
Christopher Smernoff
Chief Accounting Officer (6) |
|
2018
|
|
$
|
160,000
|
|
|
$
|
133,600
|
|
|
$
|
106,410
|
|
|
$
|
4,340
|
|
|
$
|
404,350
|
|
|
Lisa Mumford
Former Chief Financial Officer (7) |
|
2018
|
|
$
|
50,000
|
|
|
$
|
106,920
|
|
|
$
|
57,500
|
|
|
$
|
29,944
|
|
|
$
|
244,364
|
|
|
|
|
2017
|
|
$
|
198,000
|
|
|
$
|
324,720
|
|
|
$
|
174,240
|
|
|
$
|
30,122
|
|
|
$
|
727,082
|
|
|
(1)
|
Reflects the pro rata portion of the executive officer's salary that we were required to reimburse to the Manager. For Ms. Mumford in 2018 this reflects the period from January 1, 2018 through March 30, 2018.
|
|
(2)
|
Reflects the pro rata portion of the executive officer's bonus that we were required to reimburse to the Manager. A percentage of such bonuses is subject to deferral. For Ms. Mumford for 2018, this reflects the deferred portion of her bonus from 2017. As previously disclosed, we are party to a Retirement Agreement with Ms. Mumford, pursuant to which her deferred compensation will continue to vest according to schedule, and in return she will make herself available to provide reasonable assistance to our Company during such vesting period.
|
|
(3)
|
The awards shown in this column relate to OP LTIP Units. Subject to certain forfeiture provisions, OP LTIP Units, may be converted, at the election of the holder or at any time at our election, into OP Units on a one-for-one basis. Subject to certain conditions, the OP Units are redeemable by the holder for an equivalent number of Common Shares or for the cash value of such common shares, at our election The aggregate grant date fair value was calculated in accordance with FASB ASC Topic 718 based on the closing sale price for our Common Shares on the NYSE on the date of grant. For Ms. Mumford, this reflects LTIP Units granted for her service as a member of the Board after her retirement.
|
|
(4)
|
Amounts reflect dividends paid to the executive officers in respect of their unvested LTIP Units in each respective year.
|
|
(5)
|
Mr. Herlihy was appointed as our Chief Financial Officer on March 30, 2018.
|
|
(6)
|
Mr. Smernoff was appointed as our Chief Accounting Officer on March 30, 2018.
|
|
(7)
|
Ms. Mumford retired as our Chief Financial Officer on March 30, 2018.
|
|
|
|
Stock Awards
|
||||
|
Name
|
|
Number of OP LTIP Units
That Have Not Vested
|
|
Market Value of OP LTIP Units
That Have Not Vested
(1)
|
||
|
JR Herlihy
(2)
|
|
10,601
|
|
$
|
162,514
|
|
|
Christopher Smernoff
(3)
|
|
6,782
|
|
$
|
103,969
|
|
|
Lisa Mumford
(4)
|
|
9,496
|
|
$
|
145,574
|
|
|
(1)
|
Value is determined by multiplying the number of unvested OP LTIP Units by $15.33, the closing price for our Common Shares on the NYSE on December 31, 2018.
|
|
(2)
|
OP LTIP Units are subject to forfeiture prior to December 11, 2019 in the case of 5,301 OP LTIP Units and December 11, 2020 in the case of 5,300 OP LTIP Units. Subject to the forfeiture provisions, OP LTIP Units, may be converted, at the election of the holder or at any time at our election, into OP Units on a one-for-one basis. Subject to certain conditions, the OP Units are redeemable by the holder for an equivalent number of Common Shares or for the cash value of such common shares, at our election.
|
|
(3)
|
OP LTIP Units are subject to forfeiture prior to December 11, 2019 in the case of 3,391 OP LTIP Units and December 11, 2020 in the case of 3,391 OP LTIP Units. Each OP LTIP Unit is convertible into an OP Unit on a one-for-one basis once the forfeiture restrictions lapse. Subject to certain conditions, the OP Units are redeemable by the holder for an equivalent number of Common Shares or for the cash value of such common shares, at our election.
|
|
(4)
|
OP LTIP Units are subject to forfeiture prior to December 12, 2019 in the case of 5,886 OP LTIP Units and September 11, 2019 in the case of 3,610 OP LTIP Units. Subject to the forfeiture provisions, OP LTIP Units, may be converted, at the election of the holder or at any time at our election, into OP Units on a one-for-one basis. Subject to certain conditions, the OP Units are redeemable by the holder for an equivalent number of Common Shares or for the cash value of such common shares, at our election. As previously disclosed, pursuant to her retirement agreement, the forfeiture restrictions on Ms. Mumford's OP LTIP Units will lapse according to schedule and she will make herself available to provide reasonable assistance to our Company during such period.
|
|
Plan Category
|
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)
|
|
Weighted-average exercise price of our outstanding options, warrants and rights (b)
|
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
|
||
|
Equity compensation plans approved by security holders
|
|
521,371
|
(1)
|
|
N/A
|
|
1,874,223
|
(2)
|
|
(1)
|
Represents OP LTIP Units, which are a separate non-voting class of limited liability company interests structured as profits interests. Subject to certain forfeiture provisions, the OP LTIP Units, may be converted, at the election of the holder or at any time at our election, into OP Units on a one-for-one basis. Subject to certain conditions, the OP Units are redeemable by the holder for an equivalent number of shares of our common stock or, at our election for the cash value of such shares of our common stock. Of the 521,371 OP LTIP Units outstanding as of December 31, 2018, 91,738 were originally issued as LTIP Units pursuant to our 2007 Incentive Plan for Individuals (the "2007 Individual Plan"), 375,000 were originally issued as LTIP Units pursuant to our 2007 Incentive Plan for Entities (the "2007 Entity Plan"), 37,250 were originally issued as LTIP Units pursuant to our 2017
|
|
(2)
|
As of December 31, 2018, a total of 1,874,223 shares of our common stock and OP LTIP Units remain available for issuance under our 2017 Plan. The 2007 Individual Plan and the 2007 Entity Plan terminated upon stockholder approval of the 2017 Plan in May 2017 and no further grants may be made under those plans. In the event that an award granted under the 2017 Plan (including OP LTIP Units) expires, is forfeited or is terminated without having been exercised or is paid in cash without a requirement for the delivery of shares of our common stock, then any shares of our common stock covered by such lapsed, canceled, expired, unexercised or cash-settled portion of such award and any forfeited, lapsed, canceled, or expired OP LTIP Units shall be available for the grant of other awards under the 2017 Plan. Shares of our common stock tendered or withheld to satisfy the grant or exercise price or tax withholding obligation pursuant to any award will not be available for future grants or awards.
|
|
•
|
all Common Shares the investor actually owns beneficially or of record;
|
|
•
|
all Common Shares over which the investor has or shares voting or dispositive control (such as in the capacity as a general partner of a fund); and
|
|
•
|
all Common Shares the investor has the right to acquire within 60 days after March 1, 2019 (such as upon exercise of options that are currently vested or which are scheduled to vest within 60 days).
|
|
|
|
Common Shares Beneficially Owned
|
||||
|
Name and Address
|
|
Number
|
|
Percentage of
Outstanding
Common Shares
(1)
|
||
|
5% Stockholders:
|
|
|
|
|
||
|
American Financial Group, Inc.
(2)
|
|
1,877,547
|
|
|
6.3
|
%
|
|
FMR LLC
(3)
|
|
1,779,384
|
|
|
6.0
|
%
|
|
BBR Partners, LLC
(4)
|
|
1,658,466
|
|
|
5.6
|
%
|
|
VC Investments LLC
(5)
|
|
1,612,718
|
|
|
5.3
|
%
|
|
Directors and Executive Officers:
(6)
|
|
|
|
|
||
|
Michael W. Vranos
(7)
|
|
3,448,524
|
|
|
11.4
|
%
|
|
Ronald I. Simon, Ph.D
(8)
|
|
26,000
|
|
|
*
|
|
|
Edward Resendez
(9)
|
|
20,411
|
|
|
*
|
|
|
Thomas Robards
(10)
|
|
20,411
|
|
|
*
|
|
|
Laurence Penn
(11)
|
|
612,393
|
|
|
2.1
|
%
|
|
Lisa Mumford
(12)
|
|
55,611
|
|
|
*
|
|
|
JR Herlihy
(13)
|
|
—
|
|
|
*
|
|
|
Christopher Smernoff
(14)
|
|
12,881
|
|
|
*
|
|
|
All executive officers and directors as a group (10 persons)
(13)
|
|
3,694,615
|
|
|
12.1
|
%
|
|
(1)
|
Based on an aggregate amount of 29,745,776 Common Shares issued and outstanding as of March 1, 2019. Assumes that all OP LTIP Units and OP Units beneficially owned by a person are exercised for Common Shares. The total number of shares outstanding used in calculating this percentage assumes that none of the OP LTIP Units or OP Units beneficially owned by other persons are exercised for Common Shares.
|
|
(2)
|
Derived from a Schedule 13G filed with the SEC on January 25, 2019. The address for American Financial Group, Inc., or "AFG," is Great American Insurance Group Tower, 301 East Fourth Street, Cincinnati, Ohio 45202. AFG has indicated that it holds our Common Shares together with certain of its subsidiaries. AFG has sole voting and dispositive power over 1,877,547 Common Shares.
|
|
(3)
|
Derived from a Schedule 13G/A filed with the SEC on February 13, 2019. The address for FMR LLC, or "FMR," is 245 Summer Street, Boston, MA 02210. FMR has shared voting and dispositive power over 1,779,384 Common Shares.
|
|
(4)
|
Derived from a Schedule 13G filed with the SEC on January 31, 2019. The address for BBR Partners, LLC, or "BBR," is Two Grand Central Tower, 140 E. 45th Street, 26th Floor New York, NY 10017. BBR has sole voting and dispositive power over 1,658,466 Common Shares.
|
|
(5)
|
Includes Common Shares beneficially owned by EMG Holdings, L.P., or "EMGH," EFM, and VC Investments LLC, or "VC." VC has shared voting and dispositive power over 1,612,718 Common Shares (including 372,162 OP LTIP Units and 212,000 OP Units). EMGH has shared voting and dispositive power of 1,608,241 Common Shares (including 372,162 OP LTIP Units and 212,000 OP Units). EFM has shared voting and dispositive power over 4,477 Common Shares. VC is the managing member of EFM and the general partner of EMGH. Michael W. Vranos, or "Mr. Vranos," is the managing member of, and holds a controlling interest in VC. The address for each entity is 53 Forest Avenue, Old Greenwich, CT 06870.
|
|
(6)
|
The address for all officers and directors is Ellington Financial Inc., 53 Forest Avenue, Old Greenwich, CT 06870.
|
|
(7)
|
Includes Common Shares beneficially owned by EMGH, EFM, VC, and Mr. Vranos. Mr. Vranos has sole voting and dispositive power over 1,457,246 Common Shares. Mr. Vranos has shared voting and dispositive power over 3,448,524 Common Shares (including 372,162 OP LTIP Units and 212,000 OP Units). VC has shared voting and dispositive power over 1,612,718 Common Shares (including 372,162 OP LTIP Units and 212,000 OP Units). EMGH has shared voting and dispositive power of 1,608,241 Common Shares (including 372,162 OP LTIP Units and 212,000 OP Units). EFM has shared voting and dispositive power over 4,477 Common Shares. VC is the managing member of EFM and the general partner of EMGH. Mr. Vranos is the managing member of, and holds a controlling interest in VC. The address for each entity is 53 Forest Avenue, Old Greenwich, CT 06870.
|
|
(8)
|
Dr. Simon and his spouse are beneficiaries of a trust that holds all of Dr. Simon's Common Shares.
|
|
(9)
|
Includes 17,911 OP LTIP Units.
|
|
(10)
|
Includes 19,161 OP LTIP Units.
|
|
(11)
|
Includes 468,611 Common Shares, which Mr. Penn may be deemed to beneficially own. These shares are held in an investment account at EMGH and are also included in the amounts disclosed for VC Investments LLC in footnote 5 and for Mr. Vranos in footnote 7. Also includes 38,759 OP Units that Mr. Penn has shared dispositive power over.
|
|
(12)
|
Consists of 55,611 OP LTIP Units.
|
|
(13)
|
Mr. Herlihy was granted 10,601 OP LTIP Units on December 11, 2018, but none of those vest within 60 days of March 1, 2019.
|
|
(14)
|
Consists of 12,881 OP LTIP Unis.
|
|
(15)
|
Includes 477,726 OP LTIP Units and 212,000 OP Units.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|